THE COMBINATION CHLOROQUINE WITH FLT3 INHIBITORS OVERCOMES DRUG RESISTANCE IN FLT3-ITD MUTANT ACUTE MYELOID LEUKEMIA

EHA Library, Manuela Melo, 420576

BIALLELIC MUTATION OF DNMT3A DRIVES METHYLATION DAMAGE AND POOR SURVIVAL IN ACUTE MYELOID LEUKEMIA

EHA Library, Sanne Massaar, 420577

MIR-210 MEDIATED REGULATION OF PD-L1 EXPRESSION VIA THE JAK-STAT PATHWAY IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Leo Escano, 420578

SIMULTANEOUS EVALUATION OF TIM-3+LSC AND LAIP-BASED MRD ENHANCES RELAPSE PREDICTION: A SINGLE-TUBE APPROACH

EHA Library, teppei sakoda, 420579

ANTILEUKEMIC THERAPY WITH DOT1L INHIBITOR DEPENDS ON NORMAL ACTIVITY OF TRANSCRIPTION FACTORS PU.1 AND C/EBPΑ

EHA Library, Monica Cusan, 420580

STING ACTIVATION INDUCES PHAGOCYTIC CLEARANCE OF AML BY MACROPHAGES THROUGH AN ICAM/LFA1-DEPENDENT MECHANISM

EHA Library, Matthew Markham, 420581

HIGH IASPP (PPP1R13L) EXPRESSION IS AN INDEPENDENT PREDICTOR OF CLINICAL OUTCOME IN ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Kerstin Kampa-Schittenhelm, 420582

DUAL TARGETING OF FLT3-ITD AND CLK BY SCREENED DONATED CHEMICAL PROBES IN ACUTE MYELOID LEUKEMIA

EHA Library, Stephanie Laszig, 420583

AZD9829 DEMONSTRATES COMBINATION BENEFIT WITH HMA AND VENETOCLAX IN AML CELL LINES, PATIENT SAMPLES AND PDX MODELS.

EHA Library, Dipannita Dutta, 420584

COMPARISON OF TWO HIERARCHICAL DIRICHLET MIXTURE MODELS FOR THE GENOMIC STRATIFICATION OF PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Amin Turki, 420586

THE ROLE OF PRC2 IN GENE REGULATION AND CHROMATIN ARCHITECTURE IN ACUTE MYELOID LEUKAEMIA

EHA Library, Cosmin Tudose, 420587

IDENTIFICATION OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR, PAROXETINE, AS A NOVEL THERAPEUTIC AGENT IN MLL-REARRANGED ACUTE MYELOID LEUKAEMIA

EHA Library, Cheuk Yin Yuen, 420588

SYNERGISTIC POTENTIAL OF RVU120, A FIRST-IN-CLASS CDK8/CDK19 INHIBITOR, WITH VENETOCLAX IN AML: PRECLINICAL AND INITIAL CLINICAL INSIGHTS

EHA Library, Urszula Pakulska, 420589

AML LACKING PSAT1 EXPRESSION IS VULNERABLE TO SERINE-DEPLETION STRATEGIES

EHA Library, Ilias Sinanidis, 420590

CELLULAR CONTEXT DETERMINES SENSITIVITY TO ASCORBIC ACID IN AN IDH1-MUTANT ACUTE MYELOID LEUKEMIA MODEL.

EHA Library, Sarah Grasedieck, 420591

GENOME-WIDE ANALYSES IN OVER 363,000 INDIVIDUALS IDENTIFIES NEW MULTI-OMIC DETERMINANTS OF CLONAL HAEMATOPOIESIS AND HEMATOPOIETIC MOSAIC CHROMOSOMAL ALTERATIONS

EHA Library, Jonathan Bowles, 420592

FETAL MLL-ENL INITIATION INDUCES HERITABLE PROTECTIVE TRANSCRIPTIONAL PROGRAMS AGAINST TRANSFORMATION THAT DEPEND ON MLL3

EHA Library, Jonny Mendoza-Castrejon, 420593

NUP98::NSD1 RETAINS STEMNESS OF HEMATOPOIETIC STEM CELLS WITH DIFFERENTIATION BIAS TOWARDS MYELOID LINEAGE LEADING TO ACUTE MYELOID LEUKEMIA

EHA Library, Arunim Shah, 420594

REM-422, A POTENT, SELECTIVE, ORAL SMALL MOLECULE MRNA DEGRADER OF THE MYB ONCOGENE, DEMONSTRATES ANTI-TUMOR ACTIVITY IN MOUSE XENOGRAFT MODELS OF AML

EHA Library, Charles Kung, 420595

HMPL-306 IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR IDH2 MUTATIONS: FINAL RESULT OF DOSE EXPANSION IN PHASE 1 STUDY

EHA Library, Lijuan Hu, 420596

CLINICAL CHARACTERISTICS, GENETIC HETEROGENEITY, AND OUTCOMES OF KMT2A-REARRANGED AML IN ADULTS: A RETROSPECTIVE COHORT STUDY

EHA Library, Li Chen, 420597

COUPLING FUNCTIONAL RESISTANCE MARKERS AND COMPUTATIONAL ANALYSIS TO IMPROVE AND SIMPLIFY FLOW CYTOMETRIC MRD DETECTION IN AML

EHA Library, Nicholas McCarthy, 420598

A PROSPECTIVE, CROSSOVER DESIGN STUDY FOR THE SECONDARY PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ACUTE MYELOID LEUKEMIA PATIENTS POST-CYTARABINE CONSOLIDATION CHEMOTHERAPY

EHA Library, Wenlan Chen, 420599

INTERIM SAFETY AND EFFICACY OF BP1001 IN A PHASE II ACUTE MYELOID LEUKEMIA STUDY

EHA Library, Jorge Cortes, 420600

LIPOSOMAL ANNAMYCIN (L-ANN) IN COMBINATION WITH CYTARABINE FOR TREATMENT OF PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) REFACTORY TO OR RELAPSED (R/R) AFTER INDUCTION THERAPY (MB-106 STUDY).

EHA Library, Wolfram Dempke, 420601

PRELIMINARY SAFETY AND ANTILEUKEMIC ACTIVITY OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN TREATMENT-NAIVE PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Shuhying Tan, 420602

THE ROLE OF INTENSIVE CHEMOTHERAPY IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

EHA Library, Philip Haddad, 420603

SAFETY AND ACTIVITY OF REVUMENIB IN COMBINATION WITH FLUDARABINE/CYTARABINE (FLA) IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS

EHA Library, Neerav Shukla, 420604

OVERALL SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS WITH MIDH1 OR MIDH2 IN THE US, FROM AN INTERNATIONAL REAL-WORLD DATABASE (REAL-IDH)

EHA Library, Joshua Zeidner, 420605

EARLY RESPONSE ASSESSMENT AFTER CPX-351 INDUCTION THERAPY FOR ACUTE MYELOID LEUKEMIA

EHA Library, Julian Ronnacker, 420606

TOLERABILITY AND EFFICACY OF MAGROLIMAB PLUS MITOXANTRONE, ETOPOSIDE, AND CYTARABINE (MEC) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) REFRACTORY/RELAPSED (R/R) AFTER INDUCTION CHEMOTHERAPY (IC)

EHA Library, Gabriel Mannis, 420607

VENETOCLAX PLUS AZACITIDINE, CYTARABINE, ACLARUBICIN AND G-CSF (VA-CAG REGIMEN) FOR NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA: UPDATE OF A PROSPECTIVE, MULTICENTER, PHASE 2 CLINICAL TRIAL

EHA Library, Xiaoping Li, 420608

TREATMENT EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS IN PATIENT SUBGROUPS WITH ACUTE MYELOID LEUKEMIA: EXPERIENCE FROM ROUTINE CLINICAL PRACTICES IN THE UNITED STATES

EHA Library, Pankit Vachhani, 420609

OPTIMAL DURATION OF CPX-351 TREATMENT AND BEST TIMING FOR CONSOLIDATION WITH ALLOGENEIC STEM CELL TRANSPLANTATION: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY.

EHA Library, Fabio Guolo, 420610

PHASE I STUDY OF S65487, A BCL2 INHIBITOR COMBINED WITH AZACITIDINE IN ADULTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Pau Montesinos, 420611

DISMAL OUTCOMES FOLLOWING ALLOGENEIC TRANSPLANTATION IN AML PATIENTS WITH T(16;21)(P11.2;Q22.2)/FUS::ERG TRANSLOCATION

EHA Library, Yi-han Yang, 420612

PHASE 1 STUDY OF HMPL-306 IN PATIENTS WITH ADVANCED ACUTE MYELOID LEUKEMIA WITH ISOCITRATE DEHYDROGENASE (IDH) MUTATIONS: PRELIMINARY RESULTS OF THE DOSE ESCALATION COHORTS

EHA Library, Pau Montesinos, 420613

BASELINE PREDICTORS OF SURVIVAL IN 263 PATIENTS WITH AML TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX: A MULTICENTER COHORT STUDY.

EHA Library, Stefano Cordella, 420614

REVUMENIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA: TOPLINE EFFICACY AND SAFETY RESULTS FROM THE PIVOTAL AUGMENT-101 PHASE 2 STUDY

EHA Library, Ibrahim Aldoss, 420615

BLEEDING PREDICTORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Nikola Pantic, 420616

REAL-WORLD STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH TAGRAXOFUSP

EHA Library, Marco Herling, 420617

PRELIMINARY EFFICACY AND MOLECULAR CHARACTERIZATION OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS WITH FLT3 MUTATION TREATED WITH SINGLE AGENT EMAVUSERTIB (CA-4948)

EHA Library, Eric Winer, 420618

DISTINCT CLINICAL AND BIOLOGICAL CHARACTERISTICS OF ACUTE MYELOID LEUKEMIA WITH HIGHER EXPRESSION OF PIWIL4

EHA Library, Sheng-Yu Hung, 420619

RANDOMIZED PHASE 2 STUDY OF CPX-351 + POMALIDOMIDE VS CPX-351 ALONE IN NEWLY DIAGNOSED AML WITH MDS-RELATED CHANGES: RESULTS OF SAFETY RUN-IN EVALUATION

EHA Library, Daniel Peters, 420620

SAFETY AND EFFICACY OF TUSPETINIB AS MONOTHERAPY AND COMBINED WITH VENETOCLAX IN A PHASE 1/2 TRIAL OF PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Rafael Bejar, 420621

ADULT AND PEDIATRIC DETERMINANTS OF SURVIVAL IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

EHA Library, Philip Haddad, 420622

A MULTI-CENTER, OPEN-LABEL, SINGLE-ARM PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FCN-159 IN ADULTS WITH HISTIOCYTIC NEOPLASMS

EHA Library, Xin-xin Cao, 420623

IMPACT OF TP53 MUTATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DURING ORAL AZACITIDINE MAINTENANCE THERAPY: OUTCOMES FROM THE QUAZAR AML-001 TRIAL

EHA Library, Andrew H. Wei, 420624

GILTERITINIB PLUS VENETOCLAX, LOW-DOSE CYTARABINE, AND ACTINOMYCIN D AS FIRST SALVAGE THERAPY FOR RELAPSED OR REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 420625

PRELIMINARY SAFETY AND ANTILEUKEMIC ACTIVITY OF SONROTOCLAX (BGB-11417), A POTENT AND SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

EHA Library, Pau Montesinos, 420626

VENETOCLAX AND HYPOMETHYLATING AGENTS COMPARED TO OTHER STRATEGIES IN OLDER ACUTE MYELOID LEUKAEMIA PATIENTS IN THE REAL LIFE. A RETE EMATOLOGICA LOMBARDA (REL) STUDY

EHA Library, Erika Borlenghi, 420627

EFFICACY OF VENETOCLAX-BASED INDUCTION REGIMEN IN NEWLY DIAGNOSED PEDIATRIC ACUTE MYELOID LEUKEMIA

EHA Library, Xiaojia Wen, 420628

FLAG REGIMEN, COMBINED WITH GEMTUZUMAB (FLAG-GO) RESULTS IN BETTER OPTIMAL MOLECULAR RESPONSE AND OUTCOMES, COMPARED TO COMBINATION WITH IDARUBICIN (FLAG-IDA) IN UNTREATED CORE BINDING FACTOR AML

EHA Library, Gautam Borthakur, 420629

ROLE OF MRD AS A BIOMARKER TO OPTIMIZE OUTCOME IN ELN2017 INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: COMPARISON BETWEEN GIMEMA AML1310 MRD-DRIVEN PROTOCOL AND REAL-LIFE DECISION-MAKING PROCESS.

EHA Library, Raffaele Palmieri, 420630

VENETOCLAX-AZACITIDINE VERSUS AZACITIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN FIRST RELAPSE OR PRIMARY REFRACTORY TO INTENSIVE CHEMOTHERAPY. AN IPC-DATAML-MSKCC STUDY

EHA Library, Sylvain Garciaz, 420631

OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OLDER THAN 70 YEARS WITHIN THE LAST 25 YEARS, A SINGLE CENTER EXPERIENCE

EHA Library, Claudia Roggenbuck, 420632

A SYSTEMATIC REVIEW AND META-ANALYSIS ON THE RISK OF SECOND PRIMARY MALIGNANCIES IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED WITH ARSENIC TRIOXIDE

EHA Library, Ming-Hsien Lin, 420633

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION VERSUS CHEMOTHERAPY AS CONSOLIDATION TREATMENT FOR ACUTE MYELOID LEUKEMIA IN FIRST REMISSION: A PETHEMA REGISTRY STUDY.

EHA Library, Ana ALFONSO PIEROLA, 420634

REAL-WORLD USE OF ORAL-AZACITIDINE AS MAINTENANCE THERAPY FOR ACUTE MYELOID LEUKEMIA IN REMISSION: CHARACTERISTICS AND OUTCOMES OF A FRENCH PATIENT POPULATION

EHA Library, Christian Récher, 420635

QUANTUM-FIRST: PATIENT-REPORTED OUTCOMES (PROS) IN NEWLY DIAGNOSED (ND) FLT3-ITD+ ACUTE MYELOID LEUKEMIA (AML) PATIENTS (PTS) RECEIVING STANDARD CHEMOTHERAPY (CTX) PLUS QUIZARTINIB (Q) OR PLACEBO (P)

EHA Library, Esther Oliva, 420636

PROGNOSTIC RELEVANCE OF TP53 MUTATIONS WITH OR WITHOUT CONCOMITANT COMPLEX KARYOTYPE IN PATIENTS TREATED WITH CPX-351: EVIDENCE FROM A LARGE REAL-WORLD ITALIAN STUDY.

EHA Library, Elisabetta Todisco, 420637

NUP98 FUSIONS IN ADULT AML: A COHORT ANALYSIS ON FREQUENCY, CO-MUTATIONS AND GENETIC IDENTIFICATION OF A NOVEL FUSION PARTNER

EHA Library, James Heald, 420638

RESULTS OF THE PETHEMA PEVOLAM TRIAL: A PHASE III RANDOMIZED OPEN LABEL STUDY COMPARING AZACITIDINE PLUS PEVONEDISTAT VERSUS AZACITIDINE IN UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Rebeca Rodriguez Veiga, 420639

PROGNOSTIC IMPLICATIONS OF MEASURABLE RESIDUAL DISEASE AND KIT MUTATION IN PEDIATRIC CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA

EHA Library, TINGCHI YEH, 420640

PRELIMINARY RESULTS OF THE FRIDA STUDY:  IADADEMSTAT AND GILTERITINIB IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA.

EHA Library, Amir Fathi, 420641

MUTATIONAL PATTERNS AND CLONAL HIERARCHY IN 430 PATIENTS WITH IDH1 MUTATED AML INDICATE PRACTICAL IMPLICATIONS FOR MOLECULAR TESTING AND TARGETED TREATMENT

EHA Library, Gregor Hoermann, 420642

CHARACTERISTICS AND OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA CHARACTERIZED BY ISOLATED TRISOMIES AS COMPARED TO COMPLEX KARYOTYPES ACCORDING TO DIFFERENT TREATMENT STRATEGIES

EHA Library, Sabine Kayser, 420643

A MULTICENTER REAL-WORLD ANALYSIS OF GEMTUZUMAB OZOGAMICIN IN THE FIRST-LINE TREATMENT OF CBF-AML

EHA Library, Philippe J. Muller, 420644

LIPOSOMAL CYTARABINE AND DAUNORUBICIN (CPX-351) VERSUS INTENSIVE INDUCTION CHEMOTHERAPY IN PATIENTS WITH THERAPY-RELATED AML OR AML WITH MDS-RELATED CHANGES: A COMPARATIVE HOVON-SAKK ANALYSIS

EHA Library, Dimitrios Kotsos, 420645

A PHASE 1, DOSE-ESCALATION STUDY OF QLF32101, A CLL1/CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Jianxiang Wang, 420646

GENETIC PROGNOSTIC SCORING SYSTEM FOR AML WITH MYELODYSPLASIA-RELATEDABNORMALITIES

EHA Library, Yijing Zhao, 420647

A NON-INTERVENTIONAL COHORT STUDY INVESTIGATING THE CLONAL EVOLUTION OF FMS-LIKE TYROSINE KINASE 3 MUTATIONS DURING DISEASE PROGRESSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: SECOND INTERIM RESULTS

EHA Library, Cristina Papayannidis, 420648

GENOMIC PROFILES AND CLINICAL OUTCOMES IN DE NOVO VERSUS THERAPY-RELATED CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA (AML) AND OUTCOMES PREDICTORS

EHA Library, May Chiu, 420649

THE STABILITY AND CLINICAL IMPACT OF MEASURABLE RESIDUAL DISEASE BY REAL-TIME QUANTITATIVE PCR FOR KMT2A PARTIAL TANDEM DUPLICATION IN ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Hsiao-Wen Kao, 420650

BRAF DELETION IN ADULT PATIENTS WITH LANGERHANS CELL HISTIOCYTOSIS CORRELATES WITH MULTISYSTEM DISEASE AND POOR OUTCOME

EHA Library, Min Lang, 420651

QUALITY OF LIFE BENEFITS OF ATO VS CHEMOTHERAPY IN PATIENTS WITH APL ARE SUSTAINED OVER TIME: RESULTS FROM THE GIMEMA APL0406

EHA Library, Fabio Efficace, 420652

QUANTUM-FIRST: EFFICACY BY AGE IN NEWLY DIAGNOSED (ND) PATIENTS (PT) WITH FMS-LIKE TYROSINE KINASE 3-INTERNAL TANDEM DUPLICATION–POSITIVE (FLT3-ITD+) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Pau Montesinos, 420653

REDUCED VENETOCLAX EXPOSURE TO 7 DAYS VS STANDARD VENETOCLAX EXPOSURE WITH HYPOMETHYLATING AGENT IN OLDER/UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE COMPARISON.

EHA Library, Christophe Willekens, 420654

REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: UPDATED ANALYSIS OF THE CANCER ANALYSIS SYSTEM DATABASE

EHA Library, Alexandrina Lambova, 420655

A RANDOMIZED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS): A SUBGROUP ANALYSIS OF UK NCRI AML19

EHA Library, Alex Legg, 420656

TREATMENT PATTERNS AND CLINICAL OUTCOMES IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WITH AND WITHOUT MIDH1/MIDH2 TREATED WITHOUT INTENSIVE CHEMOTHERAPY: REAL-IDH A STUDY OF REAL WORLD DATABASES

EHA Library, Christian Récher, 420657

FLAVIDA CHEMOTHERAPY IS AN EFFECTIVE BRIDGE-TO-TRANSPLANT STRATEGY IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Rabia Shahswar, 420659

HIGH RISK MUTATIONS IN CRITICAL GENES DO NOT AFFECT REMISSION RATES AND MRD CLEARANCE IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CPX-351 INDUCTION

EHA Library, Carola Riva, 420660

PREDICTORS OF EARLY MORTALITY IN 1,073 PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA BASED ON THE 2022 INTERNATIONAL CONSENSUS CLASSIFICATION

EHA Library, Hsin-Yu Lu, 420661

CLINICAL CHARACTERISTICS OF RARE GENETIC ALTERATIONS ASSOCIATED WITH UPREGULATION OF HOX GENES IN ADULTS WITH ACUTE LEUKEMIA

EHA Library, Aziz Farhat, 420662

MUTATION PATTERNS AND PROGNOSTIC IMPLICATIONS IN ACUTE MYELOID LEUKEMIA WITH CHROMOSOMAL 7 DELETIONS

EHA Library, Eitan Kugler, 420663

RVU120, A FIRST-IN-CLASS CDK8 INHIBITOR FOR THE TREATMENT OF RELAPSED/REFRACTORY AML AND HIGH-RISK MDS: PRELIMINARY RESULTS FROM TWO ONGOING STUDIES

EHA Library, Dominik Chraniuk, 420664

INTERIM ANALYSIS OF A RANDOMIZED PHASE 1 TRIAL IN HEALTHY VOLUNTEERS INVESTIGATING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF A NOVEL FLT3/IRAK4 INHIBITOR, LOMONITINIB (ZE46-0134)

EHA Library, John C. Byrd, 420665

REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR ACUTE MYELOID LEUKEMIA: A SHORT-TERM ANALYSIS OF EFFICACY AND SAFETY

EHA Library, Ma Jun, 420666

PHASE II STUDY OF CLADRIBINE, IDARUBICIN, AND HIGHER DOSE CYTARABINE (CLIA) IN PATIENTS WITH RELAPSED AND/OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Tapan Kadia, 420667

BARRIERS TO AN ALLOGENEIC HSCT IN OLDER AML PATIENTS ACHIEVING REMISSION WITH INTENSIVE CHEMOTHERAPY: INSIGHTS FROM THE UK NCRI AML 18 TRIAL.

EHA Library, Priyanka Mehta, 420668

OLUTASIDENIB DEMONSTRATES CLINICAL ACTIVITY IN MUTATED IDH1 ACUTE MYELOID LEUKEMIA (AML) SECONDARY TO MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Stéphane De Botton, 420669

THE LEVELS OF EVI1 AND CLINICAL FEATURES HELP TO DISTINGUISH THE PROGNOSTIC HETEROGENEITY IN THE EVI1 OVEREXPRESSION AML ENTITY

EHA Library, Xiao-Hang Ma, 420670

LEUKAPHERESIS DOES NOT HAVE AN IMPACT ON EARLY MORTALITY RATE IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS

EHA Library, Mirjana Cvetkovic, 420671

THERAPEUTIC VENETOCLAX MONITORING BY MASS SPECTROMETRY TO REFINE DRUG DOSING IN AML PATIENTS

EHA Library, Sena Alptekin, 420672

REAL-WORLD EFFICACY OF VENETOCLAX-AZACITIDINE IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A MULTICENTRIC STUDY FROM THE GRUPO PORTUGUÊS DE LEUCEMIAS AGUDAS (GPLA)

EHA Library, Luis Monteiro, 420673

NEW COMBINATION REGIMENS VS FLAI IN THE TREATMENT OF INTERMEDIATE OR LOW RISK NPM1-MUTATED AML: A RETROSPECTIVE ANALYSIS FROM 7 ITALIAN CENTERS

EHA Library, Giulia Battaglia, 420674

SAFETY AND EFFICACY OF OLUTASIDENIB TREATMENT IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MIDH1 ACUTE MYELOID LEUKEMIA

EHA Library, Stéphane De Botton, 420675

RISK STRATIFICATION OF CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA WITH CEBPA-BZIP MUTATIONS BASED ON MULTI-GENE SEQUENCING

EHA Library, Mingyue Liao, 420676

THE CLINICAL IMPACT OF CONCURRENT GENE MUTATIONS AND CYTOGENETIC ABNORMALITIES ON NPM1-MUTATED AML: A RETROSPECTIVE COHORT STUDY OF 1,520 PATIENTS

EHA Library, Ting-Wei Lyu, 420677